Penn Capital Management Company LLC Sells 67,433 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Penn Capital Management Company LLC trimmed its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 63.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,658 shares of the company's stock after selling 67,433 shares during the period. Penn Capital Management Company LLC's holdings in Elanco Animal Health were worth $480,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. raised its stake in Elanco Animal Health by 148.8% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,741,308 shares of the company's stock worth $21,087,000 after purchasing an additional 1,041,308 shares during the period. Dark Forest Capital Management LP bought a new position in Elanco Animal Health during the 4th quarter valued at $654,000. Stifel Financial Corp raised its position in shares of Elanco Animal Health by 103.6% during the 4th quarter. Stifel Financial Corp now owns 228,277 shares of the company's stock valued at $2,764,000 after acquiring an additional 116,175 shares in the last quarter. First Trust Advisors LP lifted its holdings in Elanco Animal Health by 508.2% in the fourth quarter. First Trust Advisors LP now owns 133,038 shares of the company's stock worth $1,611,000 after acquiring an additional 111,163 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Elanco Animal Health by 6.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company's stock worth $216,774,000 after acquiring an additional 1,074,274 shares during the period. Institutional investors and hedge funds own 97.48% of the company's stock.

Insider Buying and Selling

In related news, Director Lawrence Erik Kurzius bought 10,000 shares of the company's stock in a transaction dated Tuesday, March 11th. The stock was purchased at an average price of $10.20 per share, with a total value of $102,000.00. Following the completion of the acquisition, the director now owns 111,459 shares of the company's stock, valued at $1,136,881.80. The trade was a 9.86 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.89% of the stock is owned by insiders.

Elanco Animal Health Trading Up 0.5 %

Shares of NYSE ELAN traded up $0.05 during mid-day trading on Monday, hitting $9.51. The company's stock had a trading volume of 5,245,706 shares, compared to its average volume of 4,934,235. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $18.80. The company's fifty day simple moving average is $10.03 and its 200-day simple moving average is $11.62. The stock has a market cap of $4.72 billion, a price-to-earnings ratio of 23.78, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company's revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.08 EPS. On average, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Barclays dropped their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Morgan Stanley reduced their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. Piper Sandler decreased their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, March 6th. Stifel Nicolaus decreased their target price on Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Finally, UBS Group dropped their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Elanco Animal Health has a consensus rating of "Hold" and a consensus target price of $14.67.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.